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The stimulatory effect of recombinant human insu-
lin-like growth factor-I (rhIGF-I) and recombinant 
human insulin-like growth-factor-binding protein-1 
(rhIGFBP-1) on wound healing was assessed using 
diabetic db/db mice and normal rabbits. Full-thickness 
wounds of 6 mm diameter were prepared on the backs 
of diabetic C57BL/KsJ db/db mice and on the inner 
sides of normal rabbit ears. Various concentrations of 
rhIGF-I and/or rhIGFBP-1 were applied locally to the 
open wounds of db/db mice once daily for 5 d and t o 
the covered wounds of normal rabbits once after 
wounding. Sections of the wounds were evaluated 
histologically on the seventh or eighth day by mea-
suring re-epithelialization (%), area of granulation 
tissue (mm2), and capillary numbers. Wound r epair 
was accelerated by each of the t reatment s in d escend-
ing order of rhIGF-I plus rhIGFBP-1, rh IGF-I, 
rhIGFBP-1 , and vehicle alone. In db/db mice, the 
combination of 50 ILg rhIGF-I and 165 ILg r h IGFBP-1 
ound healing proceeds with inflammation 
and granulation tissue formation, followed 
by extracellular matrix deposition and re-
modeling [1]. The process involves the in-
teractions of keratinocytes, fibroblasts , and 
inflammatory cells that have migrated to the wound site. Biologi-
cally active substances secreted from these cells modify the wound-
healing p rocess [1]. Recent studies suggested that several growth 
factors released from these cells are involved in the healing process 
and that application of exogenous growth factors promotes wound 
healing in vivo [2- 4]. 
Insulin-like growth factor (IGF) is a growth factor family that has 
structural homology with proinsulin [5,6]. The IGF family com-
prises IGF-I and IGF-II, which are single-chain polypeptides of 70 
and 67 amino acids, respectively [7]. IGF-I has short-term meta-
bolic effect on glucose transport and long-term growth-promoting 
effects as a growth hormone-dependent mitogenic agent [5,6]. 
IGF-I stimulates cultured keratinocyte and fibroblast growth 
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(equimolar ratio) significantly stimulated granulation 
tissue formation (p < 0.01) and capillary numbers 
(p < 0.05). Doses of rhIGFBP-1 greater than 16.5 ILg 
were required for significant acceleration of the 
healing stimulated by 50 ILg of rhIGF-I. In normal 
rabbits, co-administration of10 ILg rhIGF-I and 33 ILg 
rhIGFBP-1 (equimolar ratio) significantly stimulated 
all three wound-healing parameters (p < 0.01), with 
such stimulation being much greater than that in-
duced by rhIGF-I alone. Interestingly, rhIGFBP-1 
alone showed a mild stimulatory activity on wound 
healing in both models despite its lack of mitogenic 
activity in vitro. These results demonstrate that rhIG-
FBP-1 enhances the stimulatory activity of rhIGF-I 
on wound healing and suggest the clinical utility o f 
the co-administration of rhIGF-I and rhIGFBP-1 for 
wound repair. K ey words: IGFBP- 1/diabetic mouse/rabbit 
ear. J Invest D ermatol 104:199-203, 1995 
[8-10], sometimes in a paracrine manner [11], and promotes 
granulation tissue formation in animal wound-healing models 
either alone [12] or in combination with other growth factors [2]. 
IGF- I is produced mainly in the liver and circulates in the blood-
stream to target organs. IGF-I also is secreted from migrated 
platelets, macrophages, and fibroblasts in wounds [13] and IGF-I 
mRNA is detectable at the wound site [14,15]. 
A characteristic ofIGF-I and IGF-II that distinguishes them from 
other growth factors is the existence of specific IGF-binding 
proteins, designated as insulin-like growth factor- binding proteins 
(IGFBPs) [5,6,13,16]. So far, six related peptides (IGFBP-1-6) 
have been cloned and characterized. IGFBPs form complexes with 
IGF-I and IGF-II in plasma and in tissues and are believed to play 
important roles as regulators of IGF bioavailability and bioactivity. 
IGFBPs also have been shown to protect IGF-I from proteolytic 
degradation. IGFBP-3 is the most abundant IGFBP in plasma, 
where it circulates as part of a large, 150-kDa complex that is 
believed to function as a carrier and reservoir of IGF-I in plasma 
[5,16]. IGFBP-1 [17], a small, 25-kDa binding protein produced 
mainly in the liver and by fibroblasts, can distribute between the 
circulation and tissues and may playa role as a regulator of IGF-I 
bioavailability in both compartments [5,16]. 
IGFBP- 1 can inhibit the action of IGF- I on cells by forming a 
complex, which prevents IGF-I from binding to its receptor on the 
cell membrane [18 - 24]. However, depending on the experimental 
conditions or cell types, IGFBP- 1 can potentiate the action ofIGF-I 
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on cultured cells [25-27]. The precise mechanism of the interaction 
of IGF-I and IGFBP-l that results in stimulation or inhibition of 
IGF-I action is not well understood. 
In the present study, the effect of recombinant human IGFBP-l 
and/ or IGF-I on wound healing was tested using a healing-
impaired db/db mouse model [3], and the stimulatory effect of 
co-administration of IGF-I and IGFBP-l on wound healing was 
confirmed by another wound-healing model using normal rabbit 
ears. 
MATERIALS AND METHODS 
Reagents Recombinant human IGF-I (rhIGF-I) and recombinant human 
IGFBP-l (rhIGFBP-l, nonphosphorylated form) were prepared using a 
bacterial expression vector system [24]. Fractions containing greater than 
95% pure recombinant materials were used for the experiments. The vehicle 
solution consisted of 0.1% bovine serum albumin (BSA. Sigma A-4919, St. 
Louis, MO) in sterilized phosphate-buffered saline (PBS). A 30-I.Ll BSA-PBS 
solution containing different concentrations of rhIGF-I and/or rhIGFBP-l 
was applied to each wound. 
Animals and Wounding Wounding design and sample preparation 
were performed according to our previously reported method [3]. Female 
mutant diabetic mice, C57BL/ksJ db/db, were purchased from The Jackson 
Laboratory (Bar Harbor, ME). All mice were housed individually and 
maintained on a standard laboratory diet and received water ad libitum. Mice 
at 8 weeks of age were anesthetized with sodium pentobarbital solution 
(25 mg/kg, injected intraperitoneally, Abbott Laboratories, North Chicago, 
IL) and their dorsal hair was shaved. Two full-thickness round wounds were 
prepared on the back of each mouse in the anterior-posterior direction using 
a punch biopsy instrument (6 mm diameter, Maruho Co., Osaka, Japan) . 
Each mouse received the same test solution on both wounds (30 /Ll each) 
once daily until the fifth day. The wounds were left open throughout the 
experiment, and the mice were killed on the eighth day by cervical 
dislocation. The wounds were excised and fixed in 10% buffered formalin 
solution. 
Female white rabbits (Shiraishi Laboratory Animals, Tokyo, Japan), each 
weighing 2.5 kg, were anesthetized with sodium pentobarbital solution 
(40 mg/kg, Abbott Laboratories) and ketarnine hydrochloride solution 
(15 mg/kg, Sankyo Co., Tokyo, Japan). Four full-thickness round wounds 
were prepared on the inner side of each ear using a punch-biopsy instrument 
(6 mm diameter). The perichondrium was kept undamaged. The wounds 
were covered with a sterilized transparent dressing (Cathereep, Nichiban 
Co., Tokyo, Japan), and the 30-/Ll test solution applied to each wound using 
a syringe. The four wounds in each ear received the same test solution . The 
ear was bandaged and kept covered throughout the experiment. The rabbits 
were killed on the seventh day by intravenous administration of pentobar-
bital solution. The wounds were excised and fixed in 10% buffered formalin 
solution. 
Histologic Evaluation After overnight fixation, the tissue was trimmed 
and cut through at the widest margin. The tissue was embedded in paraffin 
and sectioned in 5-/Lm increments. The sections were made perpendicular 
to the anterior-posterior axis and perpendicular to the surface of the wound. 
Three sections were placed on a slide, and stained with hematoA}'lin and 
eosin. Of the three sections on anyone slide, the section with the widest 
original wound margin was used for assessment. The parameters measured 
were degree of re-epithelialization, area of granulation tissue, and number 
of capillaries. Each of the parameters was graded numerically as described 
below. 
R e-Epithelialization: The degree of re-epithelialization was measured by a 
computerized morphometric analysis (IBAS-2000, Zeiss, Germany) and was 
given a value by percentage; 0% was equivalent to no closure and 100% was 
equivalent to complete wound closure. 
Area of Granulation Tissue: The amount of granulation tissue was quantified 
by measuring the area of granulation tissue (mm2 ) in the section perpen-
dicular to the surface of the wound. Granulation tissue was traced by a 
computerized morphometric analysis (IBAS-2000). 
Capillary Number: The number of capillary lumens in the granulation tissue 
was counted in the complete wound cross-section at 100 X magnification. 
Statistical Analysis All data were analyzed by one-way analysis of 
variance using Bonferroni's procedure. The results were expressed as means 
± SEM. 
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RESULTS 
Effect ofrhIGF-I and rhIGFBP-l on wound healing in dbldl 
mice Initially, the dose response of an equimolar ratio of rhIGF-l 
and rhIGFBP-l was tested using healing-impaired diabetic mice. A~ 
the molecular sizes of the recombinant rhIGF-I and rhIGFBP-l are 
7.5 kDa and 25 kDa, respectively, the experiments were carried out 
with a 1 to 4 weight ratio of the two proteins to make them 
approximately equimolar. A test group in the initial experiment 
received a 1 to 2 weight ratio of the proteins (50 ILg rhIGF-I plus 
100 ILg rhIGFBP-1) because of the difficulties encountered in 
concentrating the proteins. Figure 1 shows that with application of 
increasing amounts of the combination ofrhIGF-1 and rhIGFBP-1, 
wound healing, as measured by three parameters-re-epithelializa-
tion, new granulation tissue, and capillary number-became accel-
erated (n = 7 per group). The combination of rhIGF-I and 
rhIGFBP-l, in doses greater than 10 ILg and 40 ILg, respectively, 
appeared to have a stimulatory effect on wound healing, although 
statistical significance was not achieved. Subsequently, using the 
larger amounts of rhIGF-I and rhIGFBP-1 (50 ILg and 165 ILg, 
respectively), the effects of rhIGF-I alone, rhIGFBP-l alone, and 
the combination of the two proteins were analyzed. Figure 2 
shows that the wounds treated with the combination ofrhIGF-I and 
rhIGFBP-1 had significant stimulatory effects on granulation tissue 
formation (p < 0.01) and capillary numbers (p < 0.05). No 
significant stimulatory effects were seen on re-epithelialization. The 
wounds treated with rhIGF-I alone also showed a stimulatory effect 
on granulation tissue formation and capillary numbers. Interest-
ingly, wounds treated with rhIGFBP-1 alone also showed a mildly 
positive effect on wound healing even though IGFBP-1 has been 
reported as being a non-mitogenic material ([27] and our unpub-
lished data). Significant difference (p < 0.05) was observed be-
tween those groups treated by rhIGFBP-1 alone and those treated 
by the co-administration ofrhIGF-I and rhIGFBP-1, especially with 
regard to granulation tissue formation. Typical examples of the 
histology obtained in the experiment (Fig 2) are illustrated in Fig 
3. It is apparent that thick and dense granulation tissue was formed 
in wounds treated with the combination ofrhIGF-I and rhIGFBP-1. 
In the next experiment, 50 ILg of rhIGF-I was applied to the 
wounds with different doses of rhIGFBP-l (1.65 ILg, 16.5 ILg, or 
165 ILg) to find the optimal ratio of the two agents. Figure 4 shows 
that an increase in the amount of rhIGFBP-l enhanced the wound 
healing stimulated by 50 ILg rhIGF-I, as measured by granulation 
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Figure 1. Co-adntinistration of rhIGF-I and rhIGFBP-l stimulated 
wound healing in db/db mic~ in dose-dependent fashion. Dose effect 
of rhIGF-I and rhIGFBP-l was examined under a fixed molar ratio of the 
two agents. A, re-epithelialization; B, granulation tissue; C, capillary 
numbers. 1, vehicle alone X 5 d; 2, [rhIGF-I (1 /Lg) + rhIGFBP-l (4 /Lg)] 
X 5 d; 3, [rhIGF-I (10 JLg) + rhIGFBP-l (40 /Lg)] X 5 d; 4, [rhIGF-I (50 JLg) 
+ rhIGFBP-l (100 /Lg)] X 5 d. n = 7 (wounds per group). Bars, mean ::!: 
SEM. 
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Figure 2. Administration of rhIGF-I or co-administration of 
rhIGF-I and rhIGFBP-l stimulated wound healing in db/db mice. A, 
re-epithelialization; B, granulation tissue; C, capillary numbers. 1, vehicle 
alone X 5 d; 2, rhIGF-I (50 J-Lg) X 5 d; 3 , rhIGFBP-1 (165 J-Lg) X 5 d; 4, 
[rhIGF-I (50 J-Lg) + rhIGFBP-1 (165 J-Lg)] X 5 d. n = 16 (wounds per 
group). Bars, mean ± SEM. *p < 0.05, **p < 0.01. 
tissue formation and capillary numbers. Presence of rhIGFBP-1 at 
doses greater than 16.5 JLg (10:1 IGF-I:IGFBP-1 molar ratio) 
appeared to be required to observe significant positive effects (p < 
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Figure 3. Histologic photomicrographs of wound specimens from 
db/db mice. Each photograph was taken from a section prepared for the 
experiment presented in Fig 2. The right side of each photograph is the 
wound edge. 1, vehicle alone X 5 d; 2, rhIGF-I (50 J-Lg) X 5 d; 3, 
rhIGFBP-1 (165 J-Lg) X 5 d; 4, [rhIGF-I (50 J-Lg) + rhIGFBP-1 (165 J-Lg)] X 
5 d . Bar, 0.3 mm. 
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Figure 4. An increase in the amount of rhIGFBP-l enhanced 
wound healing in db/db mice stimulated by rhIGF-I. Different doses of 
rhIGFBP-1 were applied with 50 J-Lg of rhIGF-I. A, re-epithelialization; B, 
granulation tissue; C, capillary numbers. 1, vehicle alone X 5 d; 2, rhIGF-I 
(50 J-Lg) X 5 d; 3, [rhIGF-I (50 J-Lg) + rhIGFBP-1 (1.65 J-Lg)] X 5 d; 4, 
[rhIGF-I (50 J-Lg) + rhIGFBP-1 (16.5 J-Lg)] X 5 d; 5, [rhIGF-I (50 J-Lg) + 
rhIGFBP-1 (165 J-Lg)] X 1 d; 6, [rhIGF-I (50 J-Lg) + rhIGFBP-1 (165 J-Lg)] X 
5 d . n = 13 (wounds per group). Bars, mean ± SEM, *p < 0.05, **p < 0.01. 
0.01). rhIGFBP-l (165 JLg) significantly enhanced the effect of 
rhIGF-I (50 JLg) with regard to granulation tissue formation (p < 
0.05). Multiple applications (once daily for 5 d) of the equimolar 
combination of rhIGF-I and rhIGFBP-1 (50 JLg and 165 JLg, 
respectively) showed better healing scores than a single application 
of the same dose of the two factors (Fig 4). 
Effect of rhIGF-I and rhIGFBP-1 on Wound Healing in 
Normal Rabbits As an open wound assay system, db/db mice 
may not necessarily be an appropriate method by which to evaluate 
the degree of re-epithelialization due to the large scab formation 
[3]. Therefore, experiments with a closed wound assay system were 
performed using normal rabbit ears. Preliminary experiments sug-
gested that 10 JLg of rhIGF-I was enough to show a stimulatory 
effect on wound healing in normal rabbits (data not shown). An 
experiment was designed to examine the stimulatory effect of 
rhIGF-I in the presence or absence of equimolar rhIGFBP-1. 
Figure 5 shows that the wounds treated with the combination of 
rhIGF-I (10 JLg) and rhIGFBP-1 (33 JLg) had significant stimulatory 
effects on re-epithelialization (p < 0.01) as well as on capillary 
numbers (p < 0.01). The wounds treated with the combination of 
rhIGF-I and rhIGFBP-1 had greater wound-healing responses, as 
measured by all three wound-healing parameters, than those 
wounds treated with rhIGF-I alone. The wounds treated with 
IGFBP-1 alone also had a mildly positive, but not statistically 
significant, effect on wound healing as was observed in db/db mice. 
Typical examples of the histology obtained in the experiment (Fig 
5) are illustrated in Fig 6. It is apparent that thick granulation tissue 
and accelerated wound closure were achieved in wounds treated 
with the combination of rhIGF-I and rhIGFBP-1. 
DISCUSSION 
The results clearly demonstrated that the co-administration of 
rhIGF-I and rhIGFBP-1 stimulates wound healing in both normal 
and healing-impaired animals. The healing stimulation induced by 
the co-administration of rhIGF-I and rhIGFBP-1 was greater than 
that induced respectively by rhIGF-I, rhIGFBP-1, or vehicle alone. 
Although variations in the data among the experiments were 
observed due to the in vivo experiments, and also because of a 
limited number of animals and limited amount of concentrated 
reagents, especially in the initial experiment, some interesting 
aspects were raised in terms of the interaction between IGF-I and 
IGFBP-l in vivo. 
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Figure 5. Co-administration of rhIGF-I and rhIGFBP-l stimulated 
wound healing in normal rabbits. A, re-epithelialization; B, granulation 
tissue; C, capillary numbers. 1, vehicle alone; 2, rhIGF-I (10 /-Lg); 3, 
rhIGFBP-1 (33 /-Lg); 4, rhIGF-I (10 /-Lg) + rhIGFBP-1 (33 /-Lg). n = 11 
(wounds per group) . Bars, mean ± SEM. *p < 0.05, **p < 0.01. 
The minimum dose ofrhlGF-1 required to induce wound healing 
in db/db mice and nonnal rabbits appeared to be 10 /-Lg (Figs 1 and 
5); however, we used 50 /-Lg of rhIGF-I in most experiments with 
db/db mice to ensure the positive effect of rhlGF-1. In the co-
administration group, Fig 4, we tested rhIGF-I:rhIGFBP-l in molar 
ratios of 100:1, 10:1, and 1:1, using a constant amount of rhIGF-I 
(50 /-Lg). Doses of rhIGFBP-l greater than 16.5 /-Lg (10:1 IGF-I: 
IGFBP-l molar ratio) were required for significant acceleration of 
the healing stimulated by 50 /-Lg of rhlGF-1. From the results we can 
infer that the application of equimolar rhIGF-I and rhIGFBP-l has 
the greatest stimulatory activity at this rhIGF-I dose. We did not 
test IGF-I:IGFBP-l molar ratios less than 1:1; i.e., IGFBP-l molar 
excess, because of difficulties in preparing highly concentrated 
rhIGFBP-l solutions. 
When comparing the results of Figs 2 and 5, the stimulatory 
activity of rhIGFBP-l on rhIGF-I-stimulated wound healing was 
more pronounced in normal rabbits than in db/db mice. This may be 
because we used a higher dose of rhIGF-I (50 /-Lg) with db/db mice 
than with nonnal rabbit (10 /-Lg). The higher rhIGF-I dose used in 
the mouse studies may have come close to maximizing the potential 
rhIGF-I response and providing a smaller window in which to 
detect stimulation by rhIGFBP-1. This situation may be analogous 
to what is observed in vitro where, at high concentrations, the 
stimulatory effect ofrhlGF-1 on cell proliferation plateaus. IGFBP-l 
potentiates the proliferative response of cultured keratinocytes to 
IGF-I [27]; however, similar to what was observed in the wound-
healing experiments, the potentiating effect of rhIGFBP-l on 
rhIGF-I-stimulated keratinocyte proliferation in vitro is mild at 
high concentrations ofrhlGF-1 (our unpublished data). An alterna-
tive possibility for the more pronounced stimulatory effect of 
rhIGFBP-l on rhIGF-I-stimulated wound healing in normal rabbits 
may be differences in circulating IGFBP-l levels in nonnal rabbits 
and db/db mice. Plasma levels of IGFBP-l are negatively regulated 
by insulin levels and are elevated in diabetes mellitus patients 
[28,29]. It is possible that the endogenous IGFBP-l level in db/db 
mice is high enough to potentiate a wound-healing response to an 
exogenous application of rhlGF-1. 
Interestingly, rhIGFBP-l alone had a mildly stimulatory effect on 
wound healing even though IGFBP-l has been reported to be 
non-mitogenic ([27] and our unpublished data). This may have 
occurred as a result of the exogenous application of rhIGFBP-l 
stimulating endogenous IGF-I present at the wound site. Some 
IGF-I would be expected to be present at the wound site as a result 
of being brought in by the circulation and as a result of secretion 
and/ or synthesis by platelets, macrophages or fibroblasts at the 
wound site. Another possibility is that the direct healing-stimula-
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tory aCtIvIty of rhIGFBP-l results from its IGF-I-independent 
migration stimulatory actions [30]. 
The stimulatory effect of IGFBP-l for the mitogenic effects 01 
IGF-I on fibroblasts [25-27] and keratinocytes [27] has been shown 
in vitro. Hamon et al [31] recently demonstrated that the systemic 
administration of IGF-I:IGFBP-3 complex was effective in revers-
ing corticosteroid-induced suppression of DNA and protein syn-
thesis in rats. The precise mechanism by which IGFBP-l , and other 
IGFBPs, stimulate the mitogenic effects of IGF-I is not yet under-
stood. Cumulative data in the literature suggest the following 
possible explanations. 1) IGFBP-l could extend the half-life of 
IGF-I at the wound site by fonning a complex [5,6,13,16]. The 
somewhat greater stimulatory effect by the combination of rhIGF-I 
and rhIGFBP-l in the multiple application group than in the single 
application group (Fig 4) suggests a limited life span of rhIGF-I and 
rhIGFBP-l at the wound site. 2) IGFBP- l, a smaller-molecular-
weight binding protein, can cross the capillary boundaries [32] and 
may act to transport IGF-I from the vasculature to IGF target cells. 
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Figure 6. Histologic photomicrographs of wound specimens from 
normal rabbits. Each photograph was taken from a section prepared for 
the experiment presented in Fig 5. The right side of each photograph is the 
wound edge and the bottom side is the cartilage of the ear. 1, vehicle alone; 
2, rhIGF-I (10 /-Lg); 3, rhIGFBP-1 (33 /-Lg); 4, rhIGF-I (10 /-Lg) + rhIGFBP-1 
(33 /-Lg). Bar, 0.3 mm. 
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3) IGFBP- 1 binds the (XS{31 integrin on the cell membrane by means 
of its Arg-Gly-Asp sequence [30]. IGF-I may associate with cell-
bound IGFBP-1 and be more accessible to IGF receptors. This also 
may be a mechanism whereby IGFBP-1 could prolong the half-life 
of IGF-I at the wound site. 4) The IGF-I-independent migration-
stimulatory activity (and other potential, uncharacterized activities) 
of IGFBP-1 [30] may allow cells to respond more vigorously to 
IGF-I stimulation. 5) IGFBP-1 may protect IGF-I from proteolytic 
degradation at the wound site. Further studies with in vitro and in 
vivo models are necessary to obtain a detailed understanding of 
IGFBP-1's stimulation mechanism. 
IGF-I has been proposed as a healing-potentiating agent [2,12]. 
The present study demonstrates that the co-administration of 
rhIGF-I and rhIGFBP-1 induces greater stimulatory activity than 
rhIGF-I alone. Although we did not perform comparative studies 
with other growth factors, the potent activity of the combination of 
rhIGF-I and rhIGFBP-1 in several wound models suggest their 
potential clinical utility as healing- stimulatory agents. 
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